Bioventus Inc. (NYSE:BVS) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. boosted its holdings in shares of Bioventus Inc. (NYSE:BVS - Free Report) by 18.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,462,081 shares of the company's stock after purchasing an additional 388,174 shares during the period. Vanguard Group Inc. owned about 3.03% of Bioventus worth $25,852,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Plato Investment Management Ltd purchased a new stake in shares of Bioventus in the fourth quarter worth about $38,000. KLP Kapitalforvaltning AS purchased a new position in shares of Bioventus during the 4th quarter valued at approximately $75,000. Quantbot Technologies LP purchased a new stake in Bioventus during the fourth quarter worth $103,000. Arizona State Retirement System purchased a new position in Bioventus in the fourth quarter valued at $109,000. Finally, HighTower Advisors LLC boosted its stake in shares of Bioventus by 11.3% during the 4th quarter. HighTower Advisors LLC now owns 13,617 shares of the company's stock worth $143,000 after acquiring an additional 1,380 shares in the last quarter. 62.94% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Bioventus

In other Bioventus news, SVP Anthony D'adamio sold 4,380 shares of Bioventus stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the sale, the senior vice president now directly owns 118,178 shares in the company, valued at $1,204,233.82. This trade represents a 3.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Mark Leonard Singleton sold 6,498 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $66,214.62. Following the completion of the sale, the chief financial officer now directly owns 118,817 shares in the company, valued at $1,210,745.23. This trade represents a 5.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,208 shares of company stock worth $226,138. Insiders own 32.90% of the company's stock.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $15.00 price target on shares of Bioventus in a report on Monday, March 17th.

Bioventus Trading Up 0.5 %

NYSE:BVS traded up $0.04 on Friday, hitting $7.82. The stock had a trading volume of 323,591 shares, compared to its average volume of 446,547. The company has a fifty day moving average price of $9.29 and a two-hundred day moving average price of $10.60. The stock has a market cap of $640.80 million, a price-to-earnings ratio of -12.82 and a beta of 0.92. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a 1-year low of $3.90 and a 1-year high of $14.38.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.